American Heart Association (AHA)

A Randomized Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes Mellitus:The IDDIA Trial

A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients with Type 2 Diabetes Mellitus in DECLARE-TIMI 58

Applicability of FDA Labeling for Dapagliflozin to Patients with HFrEF in US Clinical Practice

Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients with T2DM in the DECLARE-TIMI 58 Trial

Dapagliflozin And Prevention Of Adverse-outcomes In CKD (DAPA-CKD)

Development of a Novel Biomarker-Based Risk Score for Heart Failure in Patients with Diabetes

Effect of Dapagliflozin According to Duration of Heart Failure: An Analysis of the DAPA-HF Trial

Effects of Dapagliflozin on Physical and Social Activity Limitations in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of DAPA-HF

Relationship between cardiac biomarkers and major adverse cardiovascular events in DECLARE-TIMI 58

The Effect of Dapagliflozin on Anemia in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of DAPA-HF

An oral antisense oligonucleotide for PCSK9 inhibition in humans

Association of Immunocompromised State With Coronary Microvascular Dysfunction in Patients With Well-Controlled HIV

Patient Profile, Outcomes, Health Resource Utilization, and Quality of Life in STEMI versus NSTEMI Patients 1-3 Years Post-Discharge: Findings from the TIGRIS Registry

Risk-Benefit Evaluation in Cessation of Renin-Angiotensin-Aldosterone Inhibitors in Hyperkalemic Heart Failure Patients: A Japanese Real-World Study from Nationwide Administrative Database

Single dose safety, pharmacokinetics, and pharmacodynamics of a potent PCSK9 synthesis inhibitor, AZD8233, in subjects with elevated LDL cholesterol

Timing since last hospitalization for heart failure and risks of cardiovascular death and hospitalization of heart failure

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients with High Cardiovascular Risk The STRENGTH Trial

A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease

Amputation in Patients With Pad With and Without Diabetes: Insights From the EUCLID Trial

An On-Treatment Comparative Effectiveness Analysis of Ticagrelor vs Clopidogrel in US Real-World Setting

ALPHEUS Assessment of Loading with the P2Y12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting

Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease

Ticagrelor Added to Aspirin in Acute Ischemic Stroke or TIA of Atherosclerotic Origin